Drug profile · INN
ixekizumab
TALTZ
ixekizumab (TALTZ) is a interleukin 17a inhibitor. Route of administration: injection. Current US regulatory status: approved.
Drug details — ixekizumab
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L04)
- Route
- INJECTION
- Patents
- 0
- Programs
- 2
- Data quality
- 0.84
Quick answer
ixekizumab (TALTZ) is a interleukin 17a inhibitor. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Interleukin 17A inhibitor
Primary target: Interleukin-17A
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Recent coverage
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is ixekizumab?
ixekizumab (TALTZ) is a interleukin 17a inhibitor. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for ixekizumab?
TALTZ is a marketed brand name for ixekizumab. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ixekizumab?
ixekizumab has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.